Concepedia

Tamar Melkadze

TM

11

Publications

1.5K

Citations

11

H-Index

2021

Active since

Affiliations

David Tvildiani Medical University(Current)

Tbilisi State Medical University

Chelyabinsk Regional Clinical Oncology Center

Budgetary Healthcare Institution of Omsk Region Regional Clinical Hospital

Regeneron (United States)

Tamar Melkadze is an author at David Tvildiani Medical University specializing in cancer therapeutics, medicine, and oncology.

ORCID

Top concepts

Publications per year

2021–2024

11

Publications

11

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

Robin Kate Kelley, Lorenza Rimassa, Ann‐Lii Cheng et al. · The Lancet Oncology · 2022 · 494 citations · Full text

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer

Ying Cheng, Liang Han, Lin Wu et al. · JAMA · 2022 · 415 citations · Full text

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze et al. · Nature Medicine · 2022 · 268 citations · Full text

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial

Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze et al. · Journal of Thoracic Oncology · 2023 · 85 citations · Full text

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study

Thomas Yau, Ahmed O. Kaseb, Ann‐Lii Cheng et al. · ˜The œLancet. Gastroenterology & hepatology · 2024 · 65 citations · Full text

, , +10

Rows per page

1–5 of 11